Biopolym. Cell. 2014; 30(3):216-222.
http://dx.doi.org/10.7124/bc.000899
Molecular and Cell Biotechnologies
Development and characterization of porous functionalized collagen scaffolds for delivery of FGF-2
1Pokholenko Ia. O., 2Chetyrkina M. D., 1Dubey L. V., 1Dubey I. Ya., 1Moshynets O. V., 3Sheludko E. V., 1Shpylova S. P., 2Degtiarova M. I., 1Kordium V. A.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. Educational and Scientific Center "Institute of Biology",
    Taras Shevchenko National University of Kyiv
    64/13, Volodymyrska Str., Kyiv, Ukraine, 01601
  3. Institute of Bioorganic Chemistry and Petrochemistry, NAS of Ukraine
    1, Murmans'ka Str., Kyiv, Ukraine, 02094

Abstract

Aim. To develop the porous functionalized collagen scaffold for the delivery of FGF-2 and studying its properties in vitro and in vivo. Methods. Porous collagen scaffolds were prepared by freeze- drying collagen I solutions containing the polymer developed on the basis of cross-linked modified heparin. The scaffolds have been analyzed by SEM, AFM and SCLM. The angiogenic activity of these scaffolds loaded with FGF-2 was tested in a CAM assay. Results. The data obtained by SEM and SCLM analysis revealed that the scaffold mainly has a layered structure with pores forming a connection between the layers. The average pore size of the scaffolds varied from 76 to 150 µm. Scaffolds containing the polymer were able to incorporate human FGF-2. Proposed compositions promoted angiogenesis in CAM assay. Conclusions. The developed porous functionalized collagen scaffold incorporating FGF-2 can be used as a vehicle for the sustained delivery of the growth factor both in vitro and in vivo.
Keywords: hydrogel, fibroblast growth factor, angiogenesis, collagen, heparin
Full text: (PDF, in English)

References

[1] Peach G, Griffin M, Jones KG, Thompson MM, Hinchliffe RJ. Diagnosis and management of peripheral arterial disease. BMJ. 2012;345:e5208.
[2] Cheng X, Wang Z, Yang J, Ma M, Lu T, Xu G, Liu X. Acidic fibroblast growth factor delivered intranasally induces neurogenesis and angiogenesis in rats after ischemic stroke. Neurol Res. 2011;33(7):675-80.
[3] Daugherty AL, Rangell LK, Eckert R, Zavala-Solorio J, Peale F, Mrsny RJ. Sustained release formulations of rhVEGF165 produce a durable response in a murine model of peripheral angiogenesis. Eur J Pharm Biopharm. 2011;78(2):289–97.
[4] Chen CH, Poucher SM, Lu J, Henry PD. Fibroblast growth factor 2: from laboratory evidence to clinical application. Curr Vasc Pharmacol. 2004;2(1):33-43.
[5] Tanaka E, Ase K, Okuda T, Okumura M, Nogimori K. Mechanism of acceleration of wound healing by basic fibroblast growth factor in genetically diabetic mice. Biol Pharm Bull. 1996;19(9):1141-8.
[6] Francis ME, Uriel S, Brey EM. Endothelial cell-matrix interactions in neovascularization. Tissue Eng Part B Rev. 2008;14(1):19-32.
[7] Francis-Sedlak ME, Moya ML, Huang JJ, Lucas SA, Chandrasekharan N, Larson JC, Cheng MH, Brey EM. Collagen glycation alters neovascularization in vitro and in vivo. Microvasc Res. 2010;80(1):3-9.
[8] Zeugolis DI, Li B, Lareu RR, Chan CK, Raghunath M. Collagen solubility testing, a quality assurance step for reproducible electro-spun nano-fibre fabrication. A technical note. J Biomater Sci Polym Ed. 2008;19(10):1307-17.
[9] Sambrook J, Fritsch EE, Maniatis T. Molecular cloning. Cold Spring Harbor Lab. press, 1989; 625 p.
[10] Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 1986;89(2):271-7.
[11] Park SN, Park JC, Kim HO, Song MJ, Suh H. Characterization of porous collagen/hyaluronic acid scaffold modified by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide cross-linking. Biomaterials. 2002;23(4):1205-12.
[12] Catalogue Russian cell culture collection (RCCC). St. Petersburg: OMSK, 1999; 80 p.
[13] Wilting J, Christ B, Bokeloh M. A modified chorioallantoic membrane (CAM) assay for qualitative and quantitative study of growth factors. Studies on the effects of carriers, PBS, angiogenin, and bFGF. Anat Embryol (Berl). 1991;183(3):259-71.
[14] Seno M, Sasada R, Kurokawa T, Igarashi K. Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for heparin. Eur J Biochem. 1990;188(2):239-45.
[15] Coltrini D, Rusnati M, Zoppetti G, Oreste P, Isacchi A, Caccia P, Bergonzoni L, Presta M. Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur J Biochem. 1993;214(1):51-8.